1.
AIDS
; 27(8): 1356-9, 2013 May 15.
Artículo
en Inglés
| MEDLINE
| ID: mdl-23925383
RESUMEN
The efficacy and tolerance of telaprevir (TVR) was examined in 20 mostly cirrhotic HIV-hepatitis C genotype 1 (HCV-G1)-infected patients failing previous treatment with pegylated-interferon and ribavirin (PR). HCV-RNA less than 12âIU/ml was observed in 35.3% of patients at W2, 55.0% at W4, 65.0% at W12 and 55.0% at W24. All patients with virological failure (nâ=â9) exhibited V36M/R155K mutations. Early virological response was a determinant of HCV-RNA less than 12âIU/ml at W24 (Pâ<â0.001). No grade 3-4 dermatological side-effects were reported. TVR-PR tritherapy appeared to be rather effective and well tolerated among difficult-to-treat HIV-HCV-G1 patients.